Apogee Therapeutics secured a promise of up to $1.3 billion in nondilutive financing from Blackstone Life Sciences to advance zumilokibart into Phase 3. The move follows positive Phase 2 data reported for the anti-IL-13 antibody in moderate-to-severe atopic dermatitis, and Apogee said talks with regulators are underway as it plans additional development. The company’s financing structure is designed to fund later-stage execution and potential commercialization without traditional equity dilution. Apogee’s Phase 3 timing is tied to regulatory discussions, reflecting how development milestones can be gated by agency alignment. With Dupixent and other advanced eczema therapies defining the standard of care, Apogee’s capitalization and trial progression mark a direct attempt to build an alternative platform drug in a crowded biologics market.